Mega Lifesciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Mega Lifesciences yıllık ortalama 11.3% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 9.4% annual. Gelirler growing yılda ortalama 7.6% oranında artmaktadır. Mega Lifesciences'in özkaynak karlılığı 20% ve net marjı 11.6%'dir.

Anahtar bilgiler

11.3%

Kazanç büyüme oranı

11.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	12.4%
Gelir büyüme oranı	7.6%
Özkaynak getirisi	20.0%
Net Marj	11.6%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Mega Lifesciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SET:MEGA Gelir, gider ve kazançlar (THB Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	15,882	1,846	4,410
30 Jun 24	15,685	1,999	4,331
31 Mar 24	15,718	2,017	4,230
31 Dec 23	15,716	1,993	4,191
30 Sep 23	15,442	1,919	4,278
30 Jun 23	15,693	2,042	4,352
31 Mar 23	15,634	2,081	4,398
31 Dec 22	15,727	2,242	4,359
30 Sep 22	15,116	2,338	4,068
30 Jun 22	15,061	2,292	4,054
31 Mar 22	14,724	2,227	3,924
31 Dec 21	14,172	1,947	3,769
30 Sep 21	14,395	1,878	3,767
30 Jun 21	13,775	1,607	3,538
31 Mar 21	12,809	1,406	3,331
31 Dec 20	12,613	1,393	3,288
30 Sep 20	12,168	1,348	3,169
30 Jun 20	11,642	1,288	3,137
31 Mar 20	11,655	1,205	3,195
31 Dec 19	11,164	1,139	3,176
30 Sep 19	10,950	1,163	3,198
30 Jun 19	10,712	1,136	3,153
31 Mar 19	10,569	1,203	3,113
31 Dec 18	10,284	1,206	3,052
30 Sep 18	10,147	1,183	3,041
30 Jun 18	9,937	1,175	3,010
31 Mar 18	9,829	1,178	2,988
31 Dec 17	9,624	1,113	2,965
30 Sep 17	9,514	1,023	2,928
30 Jun 17	9,282	945	2,869
31 Mar 17	8,968	873	2,766
31 Dec 16	8,828	795	2,674
30 Sep 16	8,514	771	2,603
30 Jun 16	8,226	756	2,658
31 Mar 16	8,115	703	2,714
31 Dec 15	7,966	696	2,718
30 Sep 15	7,775	675	2,668
30 Jun 15	7,862	634	2,580
31 Mar 15	7,851	598	2,486
31 Dec 14	7,749	548	2,471
30 Sep 14	7,620	474	2,454
30 Jun 14	7,422	516	2,362
31 Mar 14	7,226	567	2,304
31 Dec 13	7,055	624	2,236

Kaliteli Kazançlar: MEGA yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: MEGA 'nin mevcut net kar marjları (11.6%) geçen yılın (12.4%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: MEGA şirketinin kazancı son 5 yılda yılda 11.3% oranında arttı.

Büyüme Hızlandırma: MEGA 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: MEGA geçtiğimiz yıl negatif kazanç büyümesine ( -3.8% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 7.5% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: MEGA 'nin Özsermaye Getirisi ( 20% ) düşük olarak değerlendiriliyor.

Mega Lifesciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

First half dividend of ฿0.80 announced

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin